NCT02889809 - Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year | Biotech Hunter

Enrollment

477

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

April 9, 2021

Study Completion Date

June 4, 2021

Conditions

Asthma

Interventions

DRUG

Fluticasone furoate

Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.

DRUG

Placebo

Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.

DRUG

Montelukast

Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)

DRUG

Short Acting Beta 2 Agonist

Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.

Trial Locations (54)

1055

GSK Investigational Site, Middelburg

7500

GSK Investigational Site, Cape Town

7530

GSK Investigational Site, Bellville

7700

GSK Investigational Site, Cape Town

7708

GSK Investigational Site, Cape Town

15241

GSK Investigational Site, Pittsburgh

15879

GSK Investigational Site, Bialystok

27607

GSK Investigational Site, Raleigh

30501

GSK Investigational Site, Gainesville

33030

GSK Investigational Site, Homestead

33134

GSK Investigational Site, Miami

33135

GSK Investigational Site, Miami

33142

GSK Investigational Site, Miami

33175

GSK Investigational Site, Miami

33470

GSK Investigational Site, Loxahatchee Groves

33710

GSK Investigational Site, St. Petersburg

48197

GSK Investigational Site, Ypsilanti

68123

GSK Investigational Site, Bellevue

72205

GSK Investigational Site, Little Rock

76712

GSK Investigational Site, Waco

78230

GSK Investigational Site, San Antonio

92648

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford

119991

GSK Investigational Site, Moscow

129110

GSK Investigational Site, Moscow